Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2019

View Archived Issues

Cyclacel Pharmaceuticals initiates phase I study of CYC-065 plus venetoclax in patients with CLL

Motor protein myosin drives metastasis

Protein links sleep and sickness

SGL-5213 demonstrates efficacy in preclinical model of impaired glucose tolerance

Novel GPR40 superagonist demonstrates remarkable preclinical efficacy in models of diabetes

Preclinical data presented on PBK-001 vaccine for the treatment of melioidosis

Tripartite motif family-like 2 downregulation reduces oral squamous cell carcinoma growth

CSIC patents new PDE8A inhibitors

FDA issues complete response letter for ALKS-5461 NDA for adjunctive treatment of MDD

GenSight announces 48-week data from RESCUE trial of GS-010 in LHON

Dart NeuroScience discloses PDE7B inhibitors

Oxford University signs option agreement with Blue Water Vaccines for universal influenza vaccine

Roche and Genentech identify RIP-1 inhibitors

Nerviano Medical Sciences synthesizes choline kinase inhibitors

Medshine Discovery presents Rho kinase inhibitors

Phosphorylation study gives insights into Chlamydia

OncoSec updates clinical progress with Tavo

Moderna exercises option for exclusive licensing agreement with Avacta

Tinagl1 protein may be therapeutic in triple-negative breast cancer

Circulating miR-3659 found useful for diagnosing dyslipidemia in patients with obesity

FDA clears IND for phase I/IIa trial of VLPM-01 malaria vaccine

BREEZE-AD1 and AD2 studies of baricitinib in atopic dermatitis meet primary endpoints

Eisai plans single phase III confirmatory study of BAN-2401 in early Alzheimer's

Biohaven plans to advance BHV-3500 into phase II for acute treatment of migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...